Germany-based Sandoz has launched its generic Icatibant injection pre-filled syringe in the United States, it was reported on Thursday.

The product is intended to treat acute attacks of rare disease hereditary angioedema in adults 18 years and older. The company is offering the product to patients in the United States immediately. It has signed a US commercialisation contract with Slayback Pharma for this medicine, which is a generic equivalent to Takeda's Firazyr (icatibant injection).

Keren Haruvi, president, Sandoz Inc, said, 'We are eager to see the positive effects of making generic Icatibant available immediately to people living with this painful and disabling rare disease. This collaboration aligns with our goal to build our injectables portfolio and provide US patients access to affordable generic medicines that work the same as brand-name products.'